In a deal without disclosing financial terms, China Resources Biopharma has licensed in U.S. firm Ab Studio's ABS-VIR-001, a trispecific antibody developed as a prophylaxis and therapeutic against SARS-CoV-2 infection. More news from 3D Medicines, SinoMab and Gloria.
